- Home
- DTIL vs VYNE Comparison
DTIL vs VYNE Comparison
Compare DTIL & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- VYNE
- Stock Information
- Founded
- DTIL 2006
- VYNE 2003
- Country
- DTIL United States
- VYNE United States
- Employees
- DTIL N/A
- VYNE N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- VYNE Health Care
- Exchange
- DTIL Nasdaq
- VYNE Nasdaq
- Market Cap
- DTIL 44.1M
- VYNE 41.9M
- IPO Year
- DTIL 2019
- VYNE 2018
- Fundamental
- Price
- DTIL $4.96
- VYNE $2.70
- Analyst Decision
- DTIL Strong Buy
- VYNE Strong Buy
- Analyst Count
- DTIL 3
- VYNE 2
- Target Price
- DTIL $37.67
- VYNE $6.88
- AVG Volume (30 Days)
- DTIL 1.3M
- VYNE 153.7K
- Earning Date
- DTIL 11-04-2024
- VYNE 02-27-2025
- Dividend Yield
- DTIL N/A
- VYNE N/A
- EPS Growth
- DTIL N/A
- VYNE N/A
- EPS
- DTIL 1.45
- VYNE N/A
- Revenue
- DTIL $75,096,000.00
- VYNE $493,000.00
- Revenue This Year
- DTIL $52.95
- VYNE $28.30
- Revenue Next Year
- DTIL N/A
- VYNE N/A
- P/E Ratio
- DTIL $2.57
- VYNE N/A
- Revenue Growth
- DTIL 43.62
- VYNE 39.27
- 52 Week Low
- DTIL $3.61
- VYNE $1.57
- 52 Week High
- DTIL $19.43
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- DTIL 46.54
- VYNE 43.45
- Support Level
- DTIL $5.10
- VYNE $2.57
- Resistance Level
- DTIL $7.44
- VYNE $4.30
- Average True Range (ATR)
- DTIL 0.66
- VYNE 0.39
- MACD
- DTIL 0.14
- VYNE -0.11
- Stochastic Oscillator
- DTIL 35.25
- VYNE 7.51
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.